W. Eiermann

发表

MR imaging of the breast with Gd-DTPA: use and limitations.

S. Heywang, A. Wolf, E. Pruss, 1989, Radiology.

MR imaging of the breast using gadolinium-DTPA.

S. Heywang, W. Eiermann, D. Hahn, 1986, Journal of computer assisted tomography.

P4-08-03: Serum Autoantibodies to Breast Cancer Associated Antigens Reflect Tumor Biology: An Opportunity for Early Detection & Prevention?

J. Robertson, W. Eiermann, L. Jackson, 2011 .

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

P. Fasching, C. Denkert, W. Eiermann, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

Gideon Blumenthal, Nina Ditsch, David Cameron, 2014, The Lancet.

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

T. Fleming, L. Norton, J. Baselga, 2001, The New England journal of medicine.

Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer

A. Tutt, L. Pusztai, C. Denkert, 2012, Annals of Surgical Oncology.

Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study

Anton Belousov, Wolfgang Eiermann, M. Cheang, 2014, Clinical Cancer Research.

Outcome Prediction for Estrogen Receptor–Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics

Jingqin Luo, Mitch Dowsett, Matthew J. Ellis, 2008, Journal of the National Cancer Institute.

Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial

L. Esserman, W. Eiermann, H. Flyger, 2014, The Lancet.

Increased Prevalence of Colorectal Adenomas in Women with Breast Cancer

L. Späth, W. Eiermann, B. Göke, 2005, Digestion.

A Risk-Adapted Approach to Breast Radiation Using Targeted Intraoperative Radiotherapy (TARGIT)

W. Eiermann, H. Flyger, M. Baum, 2016 .

Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study.

C. Denkert, W. Eiermann, F. Marmé, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Correlation of various pathologic complete response (pCR) definitions with long-term outcome and the prognostic value of pCR in various breast cancer subtypes: Results from the German neoadjuvant meta-analysis.

P. Fasching, W. Eiermann, S. Loibl, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial

L. Esserman, W. Eiermann, H. Flyger, 2010, The Lancet.

FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer.

J. Bergh, F. Wiklund, W. Eiermann, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Technical improvement of pO(2) measurements in breast cancer: investigation of the feasibility in patients and in vitro validation of the method.

W. Eiermann, F. Auer, M. Molls, 2007, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].

Prevention Trials in Women at Moderate Risk of Breast Cancer

W. Eiermann, S. Loibl, M. Kaufmann, 2006, Breast Care.

Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study.

W. Eiermann, S. Loibl, S. Kümmel, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Docetaxel – maximising outcomes towards cure in early breast cancer

W. Eiermann, 2006 .

Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.

R. Greil, W. Eiermann, M. Gnant, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Carcinoma of the breast behind a prosthesis--comparison of ultrasound, mammography and MRI (case report).

S. Heywang, W. Eiermann, R. Bassermann, 1985, Computerized radiology : official journal of the Computerized Tomography Society.

Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial

S. Lundgren, W. Eiermann, H. Flyger, 2020, BMJ.

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma

Anthony Howell, Wolfgang Eiermann, Walter Jonat, 1998, Cancer.

Results of two open label Multicentre phase II pilot studies with Herceptin in combination with docetaxel and platinum salts (Cis or Carboplatin) (TCH) as Therapy for Advanced Breast Cancer (ABC) in women with tumors over-expressing the HER2-neu proto-oncogene

W. Eiermann, D. Slamon, D. Toppmeyer, 2001 .

Integrated meta-analysis on 6402 patients with early breast cancer receiving neoadjuvant anthracycline-taxane +/- trastuzumab containing chemotherapy.

P. Fasching, W. Eiermann, M. Untch, 2009 .

Effect of Delayed Targeted Intraoperative Radiotherapy vs Whole-Breast Radiotherapy on Local Recurrence and Survival

S. Lundgren, W. Eiermann, H. Flyger, 2020, JAMA oncology.

13th St. Gallen International Breast Cancer Conference 2013: Primary Therapy of Early Breast Cancer Evidence, Controversies, Consensus - Opinion of a German Team of Experts (Zurich 2013)

M. Beckmann, T. Fehm, A. Schneeweiss, 2013, Breast Care.

Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancer.

W. Eiermann, A. Wolf, M. Schuler, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Carboplatin/etoposide as first-line chemotherapy in advanced ovarian carcinoma: a pilot study

W. Eiermann, H. Hepp, L. Lenaz, 2004, Cancer Chemotherapy and Pharmacology.

PTK7 Expression in Triple-negative Breast

W. Eiermann, N. Harbeck, R. Kates, 2013 .

PTK7 expression in triple-negative breast cancer.

W. Eiermann, N. Harbeck, R. Kates, 2013, Anticancer research.

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.

W. Eiermann, H. Rugo, Y. Im, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial

W. Eiermann, H. Rugo, L. Fehrenbacher, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract S1-03: Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer

M. Buyse, J. Mackey, N. Robert, 2013 .

BRCA2 Mutations and Triple-Negative Breast Cancer

W. Eiermann, B. Ataseven, B. Högel, 2012, PloS one.

New clinical and biological insights from the international TARGIT-A randomised trial of targeted intraoperative radiotherapy during lumpectomy for breast cancer

S. Lundgren, W. Eiermann, H. Flyger, 2021, British Journal of Cancer.

Clinical Relevance of Soluble c-erbB-2 for Patients with Metastatic Breast Cancer Predicting the Response to Second-Line Hormone or Chemotherapy

W. Wilmanns, W. Eiermann, K. Possinger, 2002, Tumor Biology.

European Cooperative Trial in Operable Breast Cancer (ECTO): Improved freedom from progression (FFP) from adding paclitaxel (T) to doxorubicin (A) followed by cyclophosphamide methotrexate and fluorouracil (CMF)

J. Baselga, W. Eiermann, A. Lluch, 2005 .

BCIRG 005 main efficacy analysis: a phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (AC->T) in women with Her-2/neu negative axillary lymph node positive early breast cancer.

M. Buyse, G. Sauter, J. Mackey, 2009 .

Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group.

R. Kreienberg, W. Eiermann, W. Jonat, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Serum levels of CA 125 and histological findings at second-look laparotomy in ovarian carcinoma.

W. Eiermann, H. Hepp, P. Stieber, 1989 .

CA-125 in gynecological malignancies.

W. Eiermann, H. Hepp, P. Stieber, 1987, European journal of cancer & clinical oncology.

Steroid hormone receptors and their relevance for sebum production in the sebaceous gland ear model of the Syrian hamster

W. Eiermann, C. Luderschmidt, J. Jawny, 2004, Archives of Dermatological Research.

17α-Propylmesterolone (SH 434): an antiandrogenic sebosuppressive substance not influencing circulating testosterone concentrations

W. Eiermann, F. Bidlingmaier, C. Luderschmidt, 1984, Naunyn-Schmiedeberg's Archives of Pharmacology.

Docetaxel and trastuzumab in the adjuvant setting: Translating SABCS into clinical practice

W. Eiermann, 2006 .

[Breast cancer in the early stage].

R. J. Jones, M. Espié, G. Giaccone, 2012, Gan no rinsho. Japan journal of cancer clinics.

A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer.

A. Howell, J. Forbes, R. Blamey, 1995, European journal of cancer.

Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician’s Choice Standard-of-Care Chemotherapy

W. Eiermann, H. Rugo, I. C. Tudor, 2019, JNCI cancer spectrum.

S1-2: Long-Term Follow-Up in ABCSG-12: Significantly Improved Overall Survival with Adjuvant Zoledronic Acid in Premenopausal Patients with Endocrine-Receptor–Positive Early Breast Cancer.

R. Greil, W. Eiermann, M. Gnant, 2011 .

2030 ORAL Efficacy of neoadjuvant trastuzumab in patients with inflammatory breast cancer: data from the NOAH (NeOAdjuvant Herceptin) Phase III trial

J. Baselga, W. Eiermann, A. Lluch, 2007 .

Abstract S5-04: Ten year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC→T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+ early breast cancer

J. Mackey, N. Robert, V. Valero, 2016 .

[Nuclear magnetic resonance tomography in breast cancer diagnosis--present status and future outlook].

S. Heywang, W. Eiermann, D. Hahn, 1985, Digitale Bilddiagnostik.

11th International Conference St. Gallen: Primary Therapy of Early Breast Cancer

M. Beckmann, A. Schneeweiss, D. Wallwiener, 2009 .

[Dynamic contrast medium studies with flash sequences in nuclear magnetic resonance tomography of the breast].

S. Heywang, A. Wolf, E. Pruss, 1988, Digitale Bilddiagnostik.

Phase III, randomized study of trastuzumab emtansine (T-DM1) {+/-} pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study.

E. Perez, P. Ellis, W. Eiermann, 2015 .

BCIRG 007: First overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC)

J. Forbes, V. Valero, W. Eiermann, 2007 .

Serum levels of CA 125 and histological findings at second‐look laparotomy in ovarian carcinoma

W. Eiermann, H. Hepp, P. Stieber, 1990, Gynecologic oncology.

Response to neoadjuvant trastuzumab and chemotherapy in ER+ and ER- HER2-positive breast cancers: Gene expression analysis.

J. Baselga, W. Eiermann, A. Lluch, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial.

M. Buyse, G. Sauter, J. Mackey, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Goserelin versus CMF as adjuvant therapy for node-negative, hormone receptor-positive breast cancer in premenopausal patients. The GABG IV-A-93 trial.

W. Eiermann, W. Jonat, G. von Minckwitz, 2004, Journal of Clinical Oncology.

Pride, Prejudice, or Science: Attitudes Towards the Results of the TARGIT-A Trial of Targeted Intraoperative Radiation Therapy for Breast Cancer

L. Esserman, W. Eiermann, H. Flyger, 2015, International journal of radiation oncology, biology, physics.

2098 ORAL BCIRG 007: First overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC)

J. Forbes, V. Valero, W. Eiermann, 2007 .

S3-2: Neoadjuvant Chemotherapy Adapted by Interim Response Improves Overall Survival of Primary Breast Cancer Patients - Results of the GeparTrio Trial.

A. Schneeweiss, C. Denkert, W. Eiermann, 2011 .

J. Mackey, N. Robert, W. Eiermann, 2013, The oncologist.

[Risk factors for breast cancer and their use in early detection. Results of a case control study].

W. Eiermann, E. Bollschweiler, D. Hölzel, 1986, Geburtshilfe und Frauenheilkunde.

Isolation of the ADP/ATP translocator from beef heart mitochondria as the bongkrekate-protein complex.

W. Eiermann, M. Klingenberg, H. Aquila, 1978, European journal of biochemistry.

OC-0472: Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT Atrial

W. Eiermann, H. Flyger, M. Baum, 2015 .

Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC)

P. Fasching, C. Perou, J. Bergh, 2012 .

A randomized phase 2 study comparing EC or CMF versus nab‐paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high‐risk early breast cancer (ICE II‐GBG 52)

C. Denkert, W. Eiermann, F. Marmé, 2015, Cancer.

Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.

A Howell, A. Howell, A. Buzdar, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial

J. Cuzick, A. Howell, J. Forbes, 2016, The Lancet.

Follow-Up of Exocrine Pancreatic Function in Type-1 Diabetes mellitus

T. Hwang, Y. Jan, A. Zinsmeister, 2005, Digestion.

Positive Early Breast Cancer : Results from the BCIRG Trastuzumab-Based Regimens in Patients with Node-Positive and High-Risk Health-Related Quality of Life With Adjuvant Docetaxel

J. Mackey, N. Robert, W. Eiermann, 2013 .

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

W. Eiermann, H. Rugo, I. C. Tudor, 2018, The New England journal of medicine.

Response-guided neoadjuvant chemotherapy for breast cancer.

Carsten Denkert, Andreas Schneeweiss, Stefan Paepke, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic and predictive impact of Ki-67 before and after neoadjuvant chemotherapy on PCR and survival: Results of the GeparTrio trial.

T. Fehm, C. Denkert, W. Eiermann, 2012 .

Analysis of germline BRCA1/2 mutated (gBRCAmut) hormone receptor-positive (HR+) and triple negative breast cancer (TNBC) treated with talazoparib (TALA).

W. Eiermann, H. Rugo, I. C. Tudor, 2018 .

Hormone-receptor status and likelihood of predicting pathological complete response (pCR) in the NOAH trial of neoadjuvant trastuzumab in patients (pts) with HER2-positive locally advanced breast cancer (LABC)

J. Baselga, W. Eiermann, V. Semiglazov, 2008 .

[Contrast enhancement of the nipple in nuclear magnetic resonance tomography of the breast with Gd-DTPA].

S. Heywang, W. Eiermann, W. Permanetter, 1987, Digitale Bilddiagnostik.

P1.01A phase 3 study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with advanced breast cancer (EMBRACA)

W. Eiermann, H. Rugo, M. Martín, 2015 .

Gd-DTPA enhanced MR imaging of the breast in patients with postoperative scarring and silicon implants.

S H Heywang, S. Heywang, T. Hilbertz, 1990, Journal of computer assisted tomography.

[Cutaneous coumarin necrosis of the breast].

W. Eiermann, W. Albrich, K. Gutschow, 2008, Deutsche medizinische Wochenschrift.

An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane

Wolfgang Eiermann, J. Robertson, A. Buzdar, 2002, Cancer.

Antibody evidence for different conformational states of ADP, ATP translocator protein isolated from mitochondria.

W. Eiermann, B. Buchanan, M. Klingenberg, 1976, Proceedings of the National Academy of Sciences of the United States of America.

Immunological characterization of the ADP, ATP translocator protein isolated from mitochondria of liver, heart and other organs Evidence for an organ specificity

W. Eiermann, M. Klingenberg, H. Aquila, 1977, FEBS letters.

Incorporation of N-ethylmaleimide into the membrane-bound ADP/ATP translocator. Isolation of the protein labeled with N-[3H]ethylmaleimide.

W. Eiermann, M. Klingenberg, H. Aquila, 1982, European journal of biochemistry.

Significance of Bone Alkaline Phosphatase, CA 15-3 and CEA in the Detection of Bone Metastases During the Follow-Up of Patients Suffering from Breast Carcinoma

W. Eiermann, C. Kirsch, P. Stieber, 1992, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

Experiences with SCC antigen, a new tumor marker for cervical carcinoma.

W. Eiermann, H. Hepp, P. Stieber, 1989, European journal of cancer & clinical oncology.

H-Y antigen expression in different tissues from transsexuals

W. Eiermann, W. Eicher, H. Cleve, 2004, Human Genetics.

Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials

P. Fasching, W. Eiermann, S. Loibl, 2010, Breast Cancer Research and Treatment.

Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study.

John R. Mackey, Marc Buyse, Arlene Chan, 2009 .

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.

Wolfgang Eiermann, Fatima Cardoso, W. Eiermann, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer

E. Perez, P. Ellis, W. Eiermann, 2019, BMC Cancer.

PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance

J. Mackey, N. Robert, W. Eiermann, 2015, Clinical Cancer Research.

Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer.

J. Baselga, W. Eiermann, A. Lluch, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer

E. Perez, P. Ellis, W. Eiermann, 2019, BMC Cancer.

Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2–Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study

E. Perez, P. Ellis, W. Eiermann, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PTK 7 Is a Transforming Gene and Prognostic Marker for Breast Cancer and Nodal Metastasis Involvement

A. Ullrich, W. Eiermann, Petra Wolf, 2014, PloS one.

Analysis of Fcγ Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients

M. Buyse, J. Mackey, N. Robert, 2012, Clinical Cancer Research.

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

J. Baselga, M. Climent, W. Eiermann, 2010, The Lancet.

A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer.

A. Howell, S. Lundgren, W. Eiermann, 1996, European journal of cancer.

Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.

W. Eiermann, M. Smylie, D. Slamon, 2004, Journal of the National Cancer Institute.

Single-dose intraoperative radiotherapy during lumpectomy for breast cancer: an innovative patient-centred treatment

S. Lundgren, W. Eiermann, H. Flyger, 2021, British Journal of Cancer.

Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.

J. Baselga, M. Climent, W. Eiermann, 2014, The Lancet. Oncology.

Ki67 Measured after Neoadjuvant Chemotherapy for Primary Breast Cancer

P. Fasching, T. Fehm, C. Denkert, 2013, Clinical Cancer Research.

Clinical relevance of steroid receptor analysis.

W. Eiermann, J. Jawny, 1983, Journal of receptor research.

A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician’s choice of therapy in patients with advanced breast cancer and a germline BRCA mutation: EMBRACA subgroups by age

W. Eiermann, H. Rugo, I. C. Tudor, 2018, The Breast.

Adjuvant trastuzumab in HER2-positive breast cancer.

Marc Buyse, Arlene Chan, Marek Pawlicki, 2011, The New England journal of medicine.

Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines

G. Sauter, J. Mackey, N. Robert, 2018, JAMA oncology.

HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials

M. Buyse, G. Sauter, J. Mackey, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.

M. Buyse, G. Sauter, J. Mackey, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.

M. Buyse, G. Sauter, N. Robert, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study.

W. Eiermann, J. Blohmer, G. von Minckwitz, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel.

W. Eiermann, J. Blohmer, G. von Minckwitz, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2–positive advanced breast cancer: Final results from MARIANNE

E. Perez, P. Ellis, W. Eiermann, 2019, Cancer.

Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up.

W. Eiermann, N. Harbeck, M. Untch, 1994, British Journal of Cancer.

A phase 3, open-label, randomized, parallel, 2-arm international study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA).

W. Eiermann, H. Rugo, Y. Im, 2015 .

Monocytes/macrophages support mammary tumor invasivity by co-secreting lineage-specific EGFR ligands and a STAT3 activator

A. Ullrich, W. Eiermann, P. Widschwendter, 2013, BMC Cancer.

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study.

J. Mackey, W. Eiermann, T. Pintér, 2011, The Lancet. Oncology.

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006.

A. Schneeweiss, C. Denkert, A. Buzdar, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Monocytes/macrophages support mammary tumor invasivity by co-secreting lineage-specific EGFR ligands and a STAT3 activator

W. Eiermann, P. Widschwendter, B. Ataseven, 2013, BMC Cancer.

Feasibility and Tolerability of Sequential Doxorubicin/Paclitaxel Followed by Cyclophosphamide, Methotrexate, and Fluorouracil and Its Effects on Tumor Response as Preoperative Therapy

J. Baselga, W. Eiermann, A. Lluch, 2005, Clinical Cancer Research.

Adjuvant Trastuzumab in HER 2-Positive Breast Cancer

M. Buyse, G. Sauter, J. Mackey, 2011 .

Oblimersen combined with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment in primary breast cancer: final results of a multicentric phase I study.

A. Schneeweiss, A. Scharf, F. Schuetz, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

BCIRG 007: Randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin first line in HER2 positive metastatic breast cancer (MBC).

J. Forbes, V. Valero, W. Eiermann, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical benefit of trastuzumab (H) among patients with HER2-positive metastatic breast cancer (MBC) not achieving objective responses when treated with H plus chemotherapy (CT)

B. Leyland-Jones, W. Eiermann, P. Klein, 2004 .

Predictive Biomarkers and Personalized Medicine Ki67Measured after Neoadjuvant Chemotherapy for Primary Breast Cancer

P. Fasching, T. Fehm, R. Thomas, 2013 .

Ki 67 measured after neoadjuvant chemotherapy for primary breast cancer

P. Fasching, T. Fehm, C. Denkert, 2013 .

Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial.

H Tesch, S Loibl, C Denkert, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study.

M. Ellis, W. Eiermann, L. Mauriac, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract GS6-07: EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's choice of therapy in patients with advanced breast cancer and a germline BRCA mutation

W. Eiermann, I. C. Tudor, Y. Im, 2018 .

Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with oestrogen receptor-positive, human epidermal growth factor receptor 2-negative early-stage breast cancer.

R. Rouzier, W. Eiermann, J. Albanell, 2016, European journal of cancer.

Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study.

J. Cuzick, W. Sauerbrei, R. Blamey, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomised trial of goserelin versus control after adjuvant, risk-adapted chemotherapy in premenopausal patients with primary breast cancer - GABG-IV B-93.

M. Schumacher, W. Eiermann, W. Jonat, 2007, European journal of cancer.

CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: a randomised trial (GABG trial IV-A-93).

W. Eiermann, W. Jonat, G. von Minckwitz, 2006, European journal of cancer.

Goserelin versus control after adjuvant, risk-adapted chemotherapy in premenopausal patients with breast cancer. GABG trial IV-B-93

W. Eiermann, W. Jonat, G. Gademann, 2004 .

Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design.

J. Bergh, C. Sotiriou, B. Gusterson, 2012, Breast.

The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use

M. Rezai, A. Schneeweiss, T. Kühn, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer.

J. Baselga, W. Eiermann, L. Gianni, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update.

Andreas Makris, Wolfgang Eiermann, Vered Stearns, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

HER2/neu, Topoisomerase 2a, Estrogen and Progesterone Receptors: Discordance between Primary Breast Cancer and Metastatic Axillary Lymph Node in Expression and Amplification Characteristics

W. Eiermann, B. Ataseven, V. Kehl, 2012, Breast Care.

BreastCare HER 2 / neu , Topoisomerase 2 a , Estrogen and Progesterone Receptors : Discordance between Primary Breast Cancer and Metastatic Axillary Lymph Node in Expression and Amplification Characteristics

W. Eiermann, B. Ataseven, V. Kehl, 2012 .

Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.

J. Baselga, W. Eiermann, A. Lluch, 2011, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[Cystosarcoma phylloides of the breast and bilateral breast cancer. Case report].

W. Eiermann, R. Bassermann, 1980, Der Pathologe.

Neoadjuvant therapy for cervical cancer.

W. Eiermann, H. Meerpohl, W. Achterrath, 1992, Seminars in oncology.

Phase II study of carboplatin/ifosfamide in untreated advanced cervical cancer

W. Eiermann, L. Lenaz, H. Meerpohl, 2004, Cancer Chemotherapy and Pharmacology.

Predictive Biomarkers and Personalized Medicine Analysis of Fc g Receptor IIIa and IIa Polymorphisms : Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients

M. Buyse, J. Mackey, N. Robert, 2012 .

Abstract OT1-03-16: EMBRACA: A phase 3, open-label, randomized, parallel, 2-arm international study of the oral PARP inhibitor talazoparib (BMN 673) versus physician's choice in BRCA mutation subjects with locally advanced and/or metastatic breast cancer

W. Eiermann, Y. Im, M. Martín, 2016 .

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.

R. Greil, W. Eiermann, M. Gnant, 2011, The Lancet. Oncology.

Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting

M. Rezai, T. Kühn, W. Eiermann, 2013, Journal of medical economics.

Studies on the clinical significance of nonesterified and total cholesterol in urine

W. Eiermann, J. Wallner, H. J. Karl, 1981, Klinische Wochenschrift.

Response of human endometrium and ovarian carcinoma cell-lines to photodynamic therapy

W. Eiermann, W. Beyer, G. Raab, 2006, Archives of Gynecology and Obstetrics.

Breakthroughs in research and treatment of early breast cancer: an overview of the last three decades

J. Bergh, W. Eiermann, M. Kiechle, 2013, Archives of Gynecology and Obstetrics.

Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anti-cancer activity: a randomised multinational controlled phase III trial

T. Fleming, L. Norton, J. Baselga, 1998 .

Biomarkers as potential predictors of pathologic complete response (pCR) in the NOAH trial of neoadjuvant trastuzumab in patients (pts) with HER2-positive locally advanced breast cancer (LABC)

L. Pusztai, J. Baselga, W. Eiermann, 2008 .

Neoadjuvant trastuzumab in locally advanced breast cancer (NOAH): Antitumour and safety analysis

J. Baselga, W. Eiermann, A. Lluch, 2007 .

A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer

P. Fasching, A. Schneeweiss, W. Eiermann, 2004, Breast Cancer Research and Treatment.

BCIRG 006: Docetaxel and trastuzumab-based regimens improve DFS and OS over AC-T in node positive and high risk node negative HER2 positive early breast cancer patients: Quality of life (QOL) at 36 months follow-up

N. Robert, W. Eiermann, H. Au, 2007 .

Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data.

W. Eiermann, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Reducing the global breast cancer burden: the importance of patterns of care research.

J. Bergh, M. Piccart, G. Hortobagyi, 2005, Clinical breast cancer.

[Vaginal hysterectomy and bilateral adnexectomy for female to male transsexuals in an interdisciplinary concept].

W. Eiermann, B. Ataseven, J. Schaff, 2011, Handchirurgie, Mikrochirurgie, plastische Chirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Handchirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Mikrochirurgie der Peripheren Nerven und Gefasse : Organ der V....

[Prognostic factors in the indication for labor induction after previous delivery by cesarean section].

W. Eiermann, H. Hepp, U. Pfeiffer, 1988, Zentralblatt fur Gynakologie.

Surgery after Primary Systemic Chemotherapy in Patients with Breast Cancer

W. Eiermann, B. Ataseven, 2006, Breast Care.

Goserelin versus control after adjuvant, risk-adapted chemotherapy in premenopausal patients with breast cancer. GABG trial IV-B-93.

W. Eiermann, W. Jonat, G. Gademann, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.

J. Forbes, M. Buyse, G. Sauter, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Internat ional Expert Panel on the Use of Pr imary ( Preoperat i ve ) Systemic Treatment of Operable Breast Cancer : Rev iew and Recommendat ions

A. Howell, V. Valero, W. Eiermann, 2003 .

International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations.

Hans-Peter Sinn, Anthony Howell, Wolfgang Eiermann, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

International E xpert P anel o n t he U se o f P rimary (Preoperative) S ystemic T reatment o f O perable B reast C ancer: Review a nd R ecommendations

A. Howell, V. Valero, W. Eiermann, 2003 .

Dose-intensified epirubicin versus standard-dose epirubicin/cyclophosphamide followed by CMF in breast cancer patients with 10 or more positive lymph nodes: results of a randomised trial (GABG-IV E-93) - the German Adjuvant Breast Cancer Group.

M. Schumacher, W. Eiermann, S. Loibl, 2010, European journal of cancer.

Locoregional treatments for triple-negative breast cancer.

W. Eiermann, K. Vallis, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment.

W. Eiermann, H. Rugo, I. C. Tudor, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of treatment characteristics on response of different breast cancer subtypes: Pooled multilayer analysis of the German neoadjuvant chemotherapy trials.

P. Fasching, W. Eiermann, S. Loibl, 2010 .

Predictive Biomarkers and Personalized Medicine Research-Based PAM 50 Subtype Predictor Identi fi es Higher Responses and Improved Survival Outcomes in HER 2-Positive Breast Cancer in the NOAH Study

M. Cheang, W. Eiermann, A. Prat, 2014 .

Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group.

M. Schumacher, W. Eiermann, W. Jonat, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

3. A randomized trial of the new specific aromatase inhibitor ‘Arimidex’ (anastrozole) versus megestrol acetate (MA) in the treatment of postmenopausal women with advanced breast cancer (ABC)

A. Howell, S. Lundgren, W. Eiermann, 1995 .

Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials

Bingshu E. Chen, R. Gray, P. Lønning, 2023, The Lancet.

Diagnostic Value of Single Photon Emission Computed Tomography (SPECT) in Benign and Malignant Tumours of the Female Breast

M. Kessler, W. Eiermann, T. Wendt, 1984 .

Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: First report of a randomized controlled trial at 10-years maximum follow-up.

W. Eiermann, M. Baum, M. Bulsara, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genetic polymorphisms and correlation with treatment induced cardiotoxicity and prognosis in breast cancer patients.

P. Fasching, R. Weinshilboum, Liewei Wang, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Abstract S1-11: Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC)

P. Fasching, C. Perou, J. Bergh, 2012 .

PTK7 as a potential prognostic and predictive marker of response to adjuvant chemotherapy in breast cancer patients, and resistance to anthracycline drugs

A. Ullrich, W. Eiermann, N. Harbeck, 2014, OncoTargets and therapy.

Statistical controversies in clinical research: statistical significance-too much of a good thing ….

M. Buyse, W. Eiermann, F. André, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[Radioimmunoscintigraphy with monoclonal antibodies].

W. Eiermann, J. Lissner, M. Landthaler, 1987, Digitale Bilddiagnostik.

Maintenance of dose intensity in adjuvant chemotherapy of breast cancer in patients treated outside a clinical trial: Results of a retrospective study

W. Eiermann, C. Jackisch, A. Rody, 2003 .

Zurich Consensus: German Expert Opinion on the St. Gallen Votes on 15 March 2009 (11th International Conference at St. Gallen: Primary Therapy of Early Breast Cancer)

M. Beckmann, A. Schneeweiss, D. Wallwiener, 2009, Breast Care.

MR Imaging of the Breast: Comparison with Mammography and Ultrasound

D Hahn, S H Heywang, S. Heywang, 1986, Journal of computer assisted tomography.

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Ennis, Lex, Rian, 2001, The New England journal of medicine.

[Changes in the serum level of female sex hormones following radiocastration using different total doses].

N. Willich, W. Eiermann, R. Rohloff, 1988, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].

Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE).

P. Fasching, A. Schneeweiss, C. Denkert, 2017, European journal of cancer.

Overview of neoadjuvant endocrine therapy for receptor positive breast cancer in post menopausal women

W. Eiermann, M. Kiechle, N. Harbeck, 2004 .

Micrometastases in bone marrow in patients with breast cancer

W. Eiermann, N. Harbeck, M. Untch, 1988, British medical journal.

Zurich Consensus: Statement of German Experts on St. Gallen Conference 2011 on Primary Breast Cancer (Zurich 2011)

M. Beckmann, A. Schneeweiss, D. Wallwiener, 2011, Breast Care.

[The course of squamous cell carcinoma antigen and CEA as prognostic criteria for response to chemotherapy in cervix cancer].

W. Eiermann, H. Hepp, P. Stieber, 1989, Geburtshilfe und Frauenheilkunde.

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.

R. Greil, W. Eiermann, M. Gnant, 2011, The Lancet. Oncology.

13th st. Gallen international breast cancer conference 2013: primary therapy of early breast cancer evidence, controversies, consensus - opinion of a german team of experts (zurich 2013).

M. Beckmann, T. Fehm, A. Schneeweiss, 2013, Breast care.

Pride, Prejudice, or Science: Attitudes Towards the Results of the TARGIT-A Trial of Targeted Intraoperative Radiation Therapy for Breast Cancer

L. Esserman, W. Eiermann, H. Flyger, 2015, International journal of radiation oncology, biology, physics.

Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial.

J. Budczies, W. Eiermann, H. Tesch, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Ki67 Measured after Neoadjuvant Chemotherapy for Primary Breast Cancer

P. Fasching, T. Fehm, C. Denkert, 2013, Clinical Cancer Research.

Reliability of Ultrasound of the Breast with Automated and Manual Scanning Compared with x-Ray Mammography

M. Kessler, W. Eiermann, R. Bassermann, 1985 .

Neoadjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer: primary efficacy analysis of the NOAH trial.

J. Baselga, W. Eiermann, A. Lluch, 2009 .